Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 3/20 | 0.37 |
| ▸ | CA1 | P00915 | 3/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | CA9 | Q16790 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TYMP | P19971 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14542978 | 0.87 | MAPK1 (0.40) | TK1MAPK1CA12CA1CA2 | |
| SCHEMBL16297679 | 0.87 | MAPK1 (0.40) | TK1MAPK1CA12CA1CA2 | |
| SCHEMBL3918733 | 0.81 | KMT2A (0.39) | TK1MAPK1CA12CA1CA2 | |
| SCHEMBL3918737 | 0.81 | TK1 (0.40) | TK1MAPK1CA12CA1CA2 | |
| SCHEMBL7761597 | 0.81 | HPGD (0.41) | TK1MAPK1CA12CA1CA2 | |
| SCHEMBL8645221 | 0.79 | TK1 (0.42) | TK1MAPK1HPGDTYMP | |
| SCHEMBL7529489 | 0.76 | HPGD (0.43) | TK1MAPK1HPGDTYMP | |
| SCHEMBL13876902 | 0.76 | TK1 (0.40) | TK1HPGD | |
| SCHEMBL8642052 | 0.75 | TK1 (0.39) | TK1MAPK1 | |
| SCHEMBL8720371 | 0.74 | KMT2A (0.47) | TK1MAPK1HPGDTYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7927581-B2 | For magnetic resonance imaging (MRI); peptide modified at its N- and its C-termini, independently, with a moiety comprising a metal chelate complex; specific binding affinity for fibrin; sufficient half-life in vivo | Factor 1A, LLC (US) | 2011-04-19 | — | — | US | disclosed |
| US-20070185311-A1 | Peptide-Based Multimeric Targeted Contrast Agents | EPIX PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| US-7238341-B2 | Peptide-based multimeric targeted contrast agents | EPIX PHARMACEUTICALS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-20060039861-A1 | Peptide-based multimeric targeted contrast agents | EPIX MEDICAL, INC., A DELAWARE CORPORATION | 2006-02-23 | — | — | US | disclosed |
| US-20050074411-A1 | Peptide-based multimeric targeted contrast agents | EPIX MEDICAL, INC. A DELAWARE CORPORATION | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060039861-A1 | Peptide-based multimeric targeted contrast agents | NGLY1, IAPP, NPPA | TK1 1722/4885MAPK1 2622/4885CA12 326/4885 |
| US-20070185311-A1 | Peptide-Based Multimeric Targeted Contrast Agents | NGLY1, IAPP, NPPA | TK1 1722/4885MAPK1 2622/4885CA12 326/4885 |
| US-20050074411-A1 | Peptide-based multimeric targeted contrast agents | NGLY1, IAPP, NPPA | TK1 1722/4885MAPK1 2622/4885CA12 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.